Ireland’s life sciences sector has an opportunity to strengthen its domestic impact by helping proven healthcare innovations move from successful trials into everyday clinical practice. In an opinion article for the Medical Independent, Dr Tanya Mulcahy of Health Innovation Hub Ireland (HIHI) highlights how the organisation has reviewed almost 1,500 healthcare innovations over the past decade and supported the evaluation of nearly 500, while reporting that only 28 have been adopted and none has scaled nationally. The figures point to an opportunity for stronger collaboration between healthcare providers, researchers, industry and enterprise agencies to help effective solutions reach more patients.

The commercial significance is considerable in a country with an established international life sciences footprint. According to the Department of Enterprise, Tourism and Employment, medical and pharmaceutical products accounted for €99.9 billion of Irish goods exports in 2024, representing 45% of the national total. While export performance and healthcare innovation adoption are different measures, Ireland’s strong industrial base provides an opportunity to connect scientific expertise with domestic healthcare needs. For pharmaceutical, medtech and digital health businesses, structured routes to evaluate solutions in real-world settings can strengthen collaboration with clinicians and help establish where innovations offer practical value.

There is already a policy foundation on which to build. The HSE published its first national Framework for Health Innovation in June 2026, establishing a structured lifecycle that guides ideas through exploration, testing, evaluation, scaling and sustained adoption. The framework also emphasises proportionate governance, workforce capability, partnerships and digital infrastructure. For life sciences companies, this creates a useful basis for engagement with healthcare organisations, although its long-term impact will depend on implementation, resources and clear decision-making pathways.

The opportunity is to make collaboration more consistent and practical. Healthcare providers can identify unmet needs and help evaluate solutions, while companies contribute scientific, technical and product expertise. Universities and innovation hubs can help connect the two, supporting evaluation and learning before wider adoption decisions are made. The World Health Organization’s guidance on scaling innovations in health systems similarly highlights the need for the right conditions to move beyond individual pilots and sustain innovations at scale. Dedicated implementation funding, workforce training and clear procurement pathways can help turn promising evidence into practical improvements without compromising patient safety or governance.

For Ireland, the next stage of life sciences growth can include not only exporting high-value medicines and technologies, but also creating stronger routes for useful innovations to benefit the health service at home. That requires shared responsibility across government, healthcare providers, industry, academia and procurement teams. By connecting evidence with implementation, Ireland can strengthen its innovation ecosystem, create more meaningful partnerships and help ensure that promising healthcare solutions deliver lasting value for patients and the wider economy.